RANI
Rani Therapeutics Holdings, Inc.1.4400
-0.0100-0.69%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
176.61MP/E (TTM)
-Basic EPS (TTM)
-0.77Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Rani raises $60M, partners with Chugai
Rani Therapeutics secured $60.3 million in gross proceeds from a private placement of 42.6 million shares and warrants, plus 82.4 million pre-funded warrants, at $0.48 per share, while converting $6 million of existing debt into equity. Simultaneously, it inked a collaboration with Chugai Pharmaceutical, pocketing $10 million upfront for combining Chugai's hemophilia antibody with Rani's oral delivery tech, plus up to $175 million in milestones and royalties. This dual move bolsters Rani's cash runway for pipeline advancement, yet hinges on stockholder approval for warrant exercises.
8-K
Rani's Chugai collab and RT-114 data
Rani Therapeutics announced a strategic research collaboration with Chugai in May 2025 for two undisclosed molecules, validating RaniPill's oral delivery with bioavailability matching subcutaneous routes. Preclinical data for obesity candidate RT-114 showed bioequivalence in canines, paving the way for Phase 1 initiation in late 2025. Cash burn eased to $11.2 million net loss, bolstered by $7.3 million from warrant exercises and a direct offering, yet reserves dipped to $10.2 million. Funding remains tight amid pipeline advances.
10-Q
Q2 FY2025 results
Rani Therapeutics narrowed its Q2 operating loss to $10.5 million from $12.5 million a year earlier, thanks to lower research and development and general administrative costs, while YTD net loss improved 15% to $24.0 million on $0.2 million in contract revenue from Chugai evaluation services. Operating cash burn eased to $13.9 million for the half, with free cash flow not disclosed in the 10-Q. Cash stood at $10.2 million against $17.2 million in debt maturing August 2026 at 14.58%, and a July offering added $3.0 million. Preclinical wins for RT-114 and RT-116 bolster the oral delivery pipeline. Yet Nasdaq delisting risks loom if the $1 bid price holds.
IPO
Employees
Sector
Industry
ENTX
Entera Bio Ltd.
2.09+0.01
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
PPCB
Propanc Biopharma, Inc.
0.73-0.03
RADX
Radiopharm Theranostics Limited
5.99-4.64
RAPP
Rapport Therapeutics, Inc.
30.76+1.16
RLMD
Relmada Therapeutics, Inc.
4.50+0.14
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
TARA
Protara Therapeutics, Inc.
5.42-0.08
VANI
Vivani Medical, Inc.
1.41+0.06
VKTX
Viking Therapeutics, Inc.
35.72-0.43